266 related articles for article (PubMed ID: 22392434)
1. Trabectedin has promising antineoplastic activity in high-grade meningioma.
Preusser M; Spiegl-Kreinecker S; Lötsch D; Wöhrer A; Schmook M; Dieckmann K; Saringer W; Marosi C; Berger W
Cancer; 2012 Oct; 118(20):5038-49. PubMed ID: 22392434
[TBL] [Abstract][Full Text] [Related]
2. Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma.
Martinez-Trufero J; Alfaro J; Felipo F; Alvarez M; Madani J; Cebollero A
Anticancer Drugs; 2010 Sep; 21(8):795-8. PubMed ID: 20622667
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin: Supportive care strategies and safety profile.
Jordan K; Jahn F; Jordan B; Kegel T; Müller-Tidow C; Rüssel J
Crit Rev Oncol Hematol; 2015 Jun; 94(3):279-90. PubMed ID: 25794812
[TBL] [Abstract][Full Text] [Related]
5. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin's contribution to the treatment of sarcomas.
Blay JY
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729
[TBL] [Abstract][Full Text] [Related]
7. Current questions in soft tissue sarcoma: further steps with Yondelis®.
Reichardt P
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):25-30. PubMed ID: 23638728
[TBL] [Abstract][Full Text] [Related]
8. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin for the management of soft-tissue sarcoma.
Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
[TBL] [Abstract][Full Text] [Related]
10. Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
Taieb S; Saada-Bouzid E; Tresch E; Ryckewaert T; Bompas E; Italiano A; Guillemet C; Peugniez C; Piperno-Neumann S; Thyss A; Maynou C; Clisant S; Penel N;
Eur J Cancer; 2015 Jan; 51(2):202-9. PubMed ID: 25499439
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Grignani G; Martín-Broto J; Schuler M; Reichardt P
Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
Martinez-Cruzado L; Tornin J; Rodriguez A; Santos L; Allonca E; Fernandez-Garcia MT; Astudillo A; Garcia-Pedrero JM; Rodriguez R
Neoplasia; 2017 Jun; 19(6):460-470. PubMed ID: 28494349
[TBL] [Abstract][Full Text] [Related]
13. Prolonged disease stability with trabectedin in two monorenal patients with retroperitoneal sarcoma.
Bruder F; Massa D; Barca M; Contu V; Airoldi M; Crova A
Tumori; 2014; 100(3):e63-6. PubMed ID: 25076252
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
Stacchiotti S; Saponara M; Frapolli R; Tortoreto M; Cominetti D; Provenzano S; Negri T; Dagrada GP; Gronchi A; Colombo C; Vincenzi B; Badalamenti G; Zuco V; Renne SL; Collini P; Morosi C; Dei Tos AP; Bello E; Pilotti S; Casali PG; D'Incalci M; Zaffaroni N
Eur J Cancer; 2017 May; 76():84-92. PubMed ID: 28284173
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
Schrell UM; Rittig MG; Anders M; Kiesewetter F; Marschalek R; Koch UH; Fahlbusch R
J Neurosurg; 1997 May; 86(5):845-52. PubMed ID: 9126901
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
López-Guerrero JA; Romero I; Poveda A
Chin J Cancer; 2015 Jan; 34(1):41-9. PubMed ID: 25556617
[TBL] [Abstract][Full Text] [Related]
18. Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy.
Brunetti AE; Delcuratolo S; Lorusso V; Palermo L; Di Giorgio A; Pisconti S; Silvestris N
Anticancer Res; 2014 Jul; 34(7):3683-8. PubMed ID: 24982387
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.
Prescrire Int; 2009 Aug; 18(102):161. PubMed ID: 19743575
[No Abstract] [Full Text] [Related]
20. Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma.
Pink D; Bertz-Lepel J; Busemann C; Bitz U; Reichardt P
Onkologie; 2012; 35(5):249-52. PubMed ID: 22868503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]